The Role of Galactose-1-Phosphate Uridylyltransferase in Drosophila melanogaster Development and Homeostasis Pubblico
Kushner, Rebekah Felice (2009)
Published
Abstract
Abstract
The Role of Galactose-1-Phosphate Uridylyltransferase in
Drosophila melanogaster
Development and Homeostasis
By Rebekah Felice Kushner
Galactose metabolism occurs primarily through the Leloir pathway,
which is highly
conserved from E. coli to humans and is catalyzed by three
enzymes: galactokinase
( GALK, EC 2.7.1.6), galactose-1-phosphate
uridylyltransferase ( GALT, EC 2.7.7.12),
and UDP-galactose 4' epimerase ( GALE, EC 5.1.3.2).
In humans, impairment in any
one of the Leloir enzymes results in the metabolic disorder,
galactosemia. The most
common clinically severe form of galactosemia is classic
galactosemia, a potentially
lethal disorder resulting from profound GALT impairment. The
current standard of care
remains the lifelong dietary restriction of galactose, which
prevents or reverses the acute
and potentially lethal symptoms of the disorder, but is
insufficient to prevent the long-
term complications, which include cognitive, motor, speech, and
female reproductive
dysfunction. Decades of research have been hindered by the lack of
a genetic animal
model that recapitulates the human phenotype, and the underlying
pathophysiology of
this disorder remains poorly understood. Here we report the
creation and initial
characterization of a Drosophila melanogaster model of
classic galactosemia that mimics
aspects of the human disorder. Like humans, GALT-deficient flies
survive under
conditions of galactose restriction but die in a dose dependent
manner when exposed to
galactose during development. These animals also exhibit
neurological complications
despite dietary restriction of galactose. Both the acute and
long-term phenotypes
observed can be rescued by the ubiquitous transgenic expression of
wild-type human
GALT. Using this D. melanogaster model, we have begun
to dissect the timing and
extent of the galactose sensitivity in GALT-null animals, as well
as the role(s) of GALT
function in organismal development and homeostasis. The existence
of an animal model
may identify new targets for novel and effective treatments,
enabling a better quality of
life for patients.
Table of Contents
I. Chapter I: Introduction 1-35 A. Galactose Metabolism 3-6
B. Galactosemia 7-11
1. GALK deficiency galactosemia 7-8
2. GALT deficiency galactosemia 8-11 3. GALE deficiency galactosemia 11 C. GALK Protein 12-14 D. GALT Protein 14-16E. Pathophysiology of classic galactosemia 16-27
1. Metabolites 17-22 2. Inhibition of enzymes 22-24 3. Glycosylation 24-27F. Model Systems 27-34
1. Saccharomyces cerevisiae 28-30
2. Mammalian cell culture 30-31
3. Mus musculus 31-32
4. Drosophila melanogaster 32-34
G.Significance 34-35
H. Figures and Figure Legends 1. Figure 1.1. The Leloir pathway of 4 galactose metabolism2. Figure 1.2. Alternative pathways of 6
galactose metabolismII. Chapter II: A Drosophila melanogaster model 36-70
of classic galactosemia A. Introduction 37-40B. Materials and Methods 41-49
B. Results 50-64C. Discussion 64-70
D. Figures and Figure Legends
1. Figure 2.1. The Leloir pathway of 38 galactose metabolism 2. Figure 2.2. Creation of an imprecise 45 excision allele of dGALT 3. Figure 2.3. Loss of dGALT results in 54 galactose sensitivity in D. melanogaster 4. Figure 2.4. Timing of death in dGALT-deficient 58D. melanogaster exposed to galactose
5. Figure 2.5. Window of galactose sensitivity 60 of dGALTΔ1AP2 /dGALTΔ1AP2 imprecise excision homozygotes 6. Figure 2.6. dGALT-null flies demonstrate 65-66an impaired negative geotaxic
response despite dietary restriction
of galactose
7. Table 2.1. D. melanogaster stocks and alleles 42used in this study
8. Table 2.2. Leloir enzyme activities in 51 D. melanogaster9. Table 2.3. Accumulation of 63
Gal-1P in larvae and flies
exposed to galactose
III. Chapter III: The Creation of a Simple, 71-94
Quantitative Assay for the Identification
of Human Galactokinase Inhibitors A. Introduction 72-76B. Materials and Methods 76-78
B. Results 78-93 C. Discussion 93-94 D. Figures and Figure Legends 1. Figure 3.1. The secondary deletion of GALK 74-75 prevents galactose sensitivity in GALT-null yeast 2. Figure 3.2. A simple, coupled enzyme 80assay for hGALK activity
3. Figure 3.3. hGALK and galactose are 81-82 limiting in the hGALK assay 4. Figure 3.4. hGALK assay is linear 84 for at least 90 minutes 5. Figure 3.5. Stability of the reaction 86 components at room temperature 6. Figure 3.6. The impact of DMSO on 87 the hGALK assay 7. Figure 3.7. and Table 1. S:B, S:N, and Z' 89 parameters for the hGALK assay meet criteria for high-throughput screening 9. Figure 3.8. Inhibition of hGALK by 91 six predicted small molecule inhibitorsIV. Chapter IV: Concluding Remarks and Future Direction 95-108
References 109-129About this Dissertation
School | |
---|---|
Department | |
Degree | |
Submission | |
Language |
|
Research Field | |
Parola chiave | |
Committee Chair / Thesis Advisor | |
Committee Members |
Primary PDF
Thumbnail | Title | Date Uploaded | Actions |
---|---|---|---|
|
The Role of Galactose-1-Phosphate Uridylyltransferase in Drosophila melanogaster Development and Homeostasis () | 2018-08-28 11:45:16 -0400 |
|
Supplemental Files
Thumbnail | Title | Date Uploaded | Actions |
---|